Activating the serotonin-2A receptor can produce antidepressant effects, but also risks hallucinations. Recent work suggests that using weak partial agonists or very low doses might separate these effects. Computer simulations of the receptor bound to different drugs show that modest activation may yield only antidepressant benefits, while excessive activation causes hallucinations. This finding points to a possible drug development strategy: administering a sufficiently weak partial agonist could provide therapeutic effects without hallucinogenic side effects, avoiding the abuse and narrow dosing problems of microdosing.
The serotonin-2A receptor (5-HT2AR) is a target for antidepressants that could work quickly or in treatment-resistant cases, but activating it can cause hallucinations. Recent research suggests certain partial agonists might produce antidepressant effects without hallucinations, though the molecular details are unclear. This study used molecular dynamics simulations of the receptor bound to two antipsychotics, three potential non-hallucinogens, and two hallucinogens. Findings suggest modest receptor activation yields only antidepressant effects, while hallucinations result from excessive activation. Modest activation via a sufficiently weak partial agonist may offer a viable drug development pathway, whereas microdosing may be problematic due to abuse potential and narrow therapeutic windows.